

Didier Blaise

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5117089/publications.pdf>

Version: 2024-02-01

958
papers

25,953
citations

9786

73
h-index

15732

125
g-index

1002
all docs

1002
docs citations

1002
times ranked

15064
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.	2.0	1,419
2	Targeting natural killer cells and natural killer T cells in cancer. <i>Nature Reviews Immunology</i> , 2012, 12, 239-252.	22.7	707
3	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). <i>Leukemia</i> , 2005, 19, 2304-2312.	7.2	417
4	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 510-519.	9.1	366
5	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 906-912.	2.4	364
6	Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Soci��t�� Fran��saise de Greffe de Moelle. <i>Journal of Clinical Oncology</i> , 2000, 18, 537-537.	1.6	357
7	Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. <i>Blood</i> , 2002, 100, 2357-2366.	1.4	344
8	Increasing Incidence of Chronic Graft-versus-Host Disease in��Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
9	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives��a position statement from the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2015, 50, 781-789.	2.4	294
10	An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 667-678.	2.4	291
11	Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Soci��t�� Fran��saise de Greffe de Mo��lle et de Th��rapie Cellulaire. <i>Journal of Clinical Oncology</i> , 2008, 26, 2264-2271.	1.6	284
12	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	30.7	253
13	Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. <i>Blood</i> , 2001, 98, 3569-3574.	1.4	252
14	Hematopoietic stem cell transplantation for patients with AML in first complete remission. <i>Blood</i> , 2016, 127, 62-70.	1.4	237
15	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 2486-2496.	1.4	233
16	Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial. <i>Annals of Internal Medicine</i> , 1997, 126, 600.	3.9	214
17	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	7.2	199
18	Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytosan versus Cytosan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments]. <i>Blood</i> , 1992, 79, 2578-2582.	1.4	191

#	ARTICLE	IF	CITATIONS
19	Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytosan versus Cytosan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments]. <i>Blood</i> , 1992, 79, 2578-2582.	1.4	189
20	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. <i>Blood</i> , 2003, 102, 470-476.	1.4	182
21	Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. <i>Blood</i> , 2003, 102, 462-469.	1.4	175
22	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. <i>Blood</i> , 2002, 100, 3128-3134.	1.4	174
23	A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. <i>Blood</i> , 2002, 99, 3517-3523.	1.4	170
24	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. <i>Leukemia</i> , 2012, 26, 2462-2468.	7.2	170
25	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 521-534.	2.4	168
26	HLA Association with Hematopoietic Stem Cell Transplantation Outcome: The Number of Mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 Is Strongly Associated with Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 965-974.	2.0	158
27	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 222-222.	1.6	147
28	Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Soci�t� Fran�aise de Greffe de Moelle (SFGM). <i>Bone Marrow Transplantation</i> , 2000, 26, 1157-1163.	2.4	146
29	Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 724-729.	2.0	141
30	Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci�t� Fran�aise de Greffe de Moelle (SFGM). <i>British Journal of Haematology</i> , 2000, 108, 400-407.	2.5	137
31	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 3425-3432.	1.6	132
32	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. <i>Cancer</i> , 2018, 124, 1428-1437.	4.1	131
33	Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2465-2472.	1.6	130
34	Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. <i>Journal of Hematology and Oncology</i> , 2018, 11, 40.	17.0	130
35	Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 879-883.	3.5	126
36	Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. <i>Blood</i> , 2004, 103, 435-441.	1.4	125

#	ARTICLE	IF	CITATIONS
37	Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. <i>Leukemia</i> , 2003, 17, 869-875.	7.2	124
38	Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. <i>Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)</i> . <i>Blood</i> , 1997, 90, 2931-8.	1.4	121
39	Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation—a report from the Soci��t�� Fran��saise de Greffe de Moelle.. <i>Journal of Clinical Oncology</i> , 1994, 12, 1217-1222.	1.6	118
40	Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. <i>Leukemia</i> , 2003, 17, 2168-2177.	7.2	111
41	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2012, 97, 1666-1673.	3.5	110
42	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	1.4	110
43	Post-transplant cyclophosphamide <i>versus</i> anti-thymocyte globulin as graft- <i>versus</i> -host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	3.5	109
44	High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 251-255.	2.4	108
45	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. <i>Haematologica</i> , 2012, 97, 1073-1079.	3.5	108
46	Anti-thymocyte globulin as graft- <i>versus</i> -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 224-234.	3.5	108
47	Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. <i>Leukemia</i> , 2013, 27, 604-609.	7.2	105
48	Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 303-306.	3.5	102
49	The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. <i>Leukemia</i> , 2005, 19, 916-920.	7.2	101
50	Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC. <i>Journal of Clinical Oncology</i> , 2008, 26, 4940-4943.	1.6	98
51	Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells. <i>Bone Marrow Transplantation</i> , 2010, 45, 349-353.	2.4	97
52	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	2.4	97
53	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 12-24.	2.4	94
54	Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. <i>Blood</i> , 1998, 92, 1933-40.	1.4	94

#	ARTICLE	IF	CITATIONS
55	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	1.4	93
56	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 389-396.	2.4	92
57	Effect of Azithromycin on Airflow Decline—Free Survival After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 557.	7.4	92
58	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	5.2	92
59	Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <i>Haematologica</i> , 2008, 93, 1837-1842.	3.5	90
60	Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. <i>British Journal of Haematology</i> , 2000, 111, 292-302.	2.5	89
61	Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2001, 19, 3340-3349.	1.6	87
62	Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Soci�te Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Leukemia</i> , 2010, 24, 1867-1874.	7.2	86
63	Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. <i>Blood</i> , 2016, 127, 3450-3457.	1.4	86
64	Haploidentical T Cell—Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen—Matched Related or Unrelated Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 119-124.	2.0	86
65	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. <i>Annals of Oncology</i> , 2006, 17, 1134-1140.	1.2	84
66	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 1317-1328.	3.5	84
67	Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. <i>Blood</i> , 2001, 97, 3669-3671.	1.4	83
68	Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). <i>Haematologica</i> , 2007, 92, 627-634.	3.5	83
69	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	3.5	82
70	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia — a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	2.5	82
71	Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. <i>Experimental Hematology</i> , 2001, 29, 458-470.	0.4	81
72	Allogeneic Stem-Cell Transplantation in Patients With Waldenstr�m Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 4926-4934.	1.6	81

#	ARTICLE	IF	CITATIONS
73	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2015, 100, 859-869.	3.5	80
74	Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. <i>Leukemia</i> , 1996, 10, 1874-82.	7.2	80
75	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 256-267.	4.3	78
76	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	5.2	76
77	Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. <i>Bone Marrow Transplantation</i> , 2002, 30, 95-102.	2.4	75
78	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014, 5, 122.	4.8	75
79	Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. <i>Haematologica</i> , 2007, 92, 1004-1006.	3.5	74
80	Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2007, 92, 533-541.	3.5	74
81	CD34+ Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 382-386.	2.0	74
82	Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 3183-3188.	1.6	73
83	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 7007-7013.	1.4	73
84	The increase from 2.5 to 5% mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 639-645.	2.4	73
85	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
86	Allogeneic Stem Cell Immunotherapy for Advanced Metastatic Breast Cancer: The Way Forward. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 84-85.	2.0	71
87	Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation. <i>Cancer</i> , 2013, 119, 602-611.	4.1	70
88	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i> , 2018, 103, 514-521.	3.5	70
89	Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. <i>Blood</i> , 2015, 126, 1027-1032.	1.4	69
90	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	17.0	68

#	ARTICLE	IF	CITATIONS
91	Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. <i>Leukemia</i> , 2015, 29, 51-57.	7.2	67
92	Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. <i>Leukemia</i> , 2002, 16, 2129-2133.	7.2	66
93	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 77-84.	2.4	66
94	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	1.4	66
95	Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. <i>British Journal of Haematology</i> , 1989, 73, 82-87.	2.5	64
96	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 2000, 110, 308-314.	2.5	64
97	Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. <i>Leukemia</i> , 2015, 29, 686-688.	7.2	64
98	Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. <i>Blood</i> , 1992, 79, 2578-82.	1.4	64
99	Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. <i>Lancet, The</i> , 1995, 345, 1144-1146.	13.7	63
100	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. <i>British Journal of Haematology</i> , 2000, 111, 1130-1137.	2.5	63
101	Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2008, 41, 953-960.	2.4	62
102	Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. <i>Cancer</i> , 2013, 119, 986-992.	4.1	62
103	Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. <i>Haematologica</i> , 2016, 101, 1390-1397.	3.5	62
104	Early and fatal immune haemolysis after so-called "minor" ABO-incompatible peripheral blood stem cell allotransplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 1155-1156.	2.4	61
105	High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2008, 93, 455-458.	3.5	61
106	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
107	The benefit of induction chemotherapy in patients age \geq 75 years. <i>Cancer</i> , 2004, 101, 325-331.	4.1	60
108	Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 7676-7684.	1.6	59

#	ARTICLE	IF	CITATIONS
109	Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. <i>Blood</i> , 2004, 103, 4666-4668.	1.4	58
110	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Experimental Hematology</i> , 2008, 36, 535-544.	0.4	58
111	Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: A report on 62 patients from a single center. <i>Annals of Oncology</i> , 1998, 9, 619-625.	1.2	57
112	Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1722-1729.	1.6	56
113	Rituximab as salvage therapy for refractory chronic GVHD. <i>Bone Marrow Transplantation</i> , 2008, 41, 909-911.	2.4	56
114	Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 429-439.	2.0	55
115	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 489-495.	2.0	53
116	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 372-380.	2.4	53
117	Critically ill allogeneic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality. <i>Bone Marrow Transplantation</i> , 2018, 53, 1233-1241.	2.4	53
118	High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia – an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	1.8	53
119	Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Leukemia</i> , 2005, 19, 1-6.	7.2	52
120	Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 160-166.	6.0	52
121	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2018, 93, 246-253.	4.1	52
122	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2134-2142.	2.0	52
123	Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a "donor" versus "no donor" comparison. <i>Leukemia</i> , 2009, 23, 194-196.	7.2	51
124	Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 289-294.	2.0	51
125	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
126	Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 22, 256-262.	2.3	50

#	ARTICLE	IF	CITATIONS
127	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. <i>Leukemia</i> , 2007, 21, 129-135.	7.2	50
128	A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 31, 343-349.	1.3	49
129	The cytokine storm and acute graft-versus-host disease (aGVHD) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT). <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 13-14.	2.0	49
130	High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 301-306.	2.4	49
131	Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised study. <i>Bone Marrow Transplantation</i> , 2002, 29, 145-149.	2.4	48
132	Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission. <i>Journal of Clinical Oncology</i> , 2009, 27, 3987-3993.	1.6	48
133	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>Haematologica</i> , 2011, 96, 1504-1511.	3.5	48
134	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
135	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , 2020, 34, 283-292.	7.2	48
136	Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2000, 25, 1115-1119.	2.4	47
137	Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1050-1061.	2.4	47
138	Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. <i>Bone Marrow Transplantation</i> , 1994, 14, 895-901.	2.4	47
139	Autologous Transplantation of Blood Stem Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet Recovery. <i>Stem Cells and Development</i> , 1996, 5, 663-670.	1.0	46
140	The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission. <i>Leukemia and Lymphoma</i> , 1997, 25, 469-478.	1.3	46
141	T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 627-632.	2.0	46
142	Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , 2019, 104, e398-e401.	3.5	46
143	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <i>Clinical Hematology International</i> , 2019, 1, 58.	1.7	46
144	Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and Thymoglobulin. <i>Blood</i> , 2011, 118, 1952-1952.	1.4	46

#	ARTICLE	IF	CITATIONS
145	Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. <i>Bone Marrow Transplantation</i> , 2000, 25, 681-682.	2.4	45
146	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. <i>Blood</i> , 2012, 119, 2943-2948.	1.4	45
147	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. <i>Leukemia</i> , 2016, 30, 2086-2089.	7.2	45
148	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
149	Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. <i>European Cytokine Network</i> , 2000, 11, 91-8.	2.0	45
150	Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+ /CD38- primitive haematopoietic progenitors. <i>British Journal of Haematology</i> , 2002, 119, 115-118.	2.5	44
151	Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 2267-2274.	7.2	44
152	Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. <i>Oncogene</i> , 2004, 23, 9381-9391.	5.9	44
153	Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study by the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1349-1355.	2.0	44
154	Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. <i>Bone Marrow Transplantation</i> , 2016, 51, 186-193.	2.4	44
155	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
156	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020, 13, 87.	17.0	44
157	Donor KIR3DL1/3DS1 Gene and Recipient Bw4 KIR Ligand as Prognostic Markers for Outcome in Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1366-1375.	2.0	43
158	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1228-1234.	1.3	43
159	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). <i>Leukemia</i> , 2015, 29, 2375-2381.	7.2	43
160	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 365-371.	2.4	43
161	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 184-191.	3.5	43
162	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , 2017, 1, 669-680.	5.2	43

#	ARTICLE	IF	CITATIONS
163	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	4.6	43
164	Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. <i>Leukemia</i> , 2006, 20, 336-344.	7.2	42
165	Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. <i>Bone Marrow Transplantation</i> , 2012, 47, 549-555.	2.4	42
166	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2014, 32, 187-191.	1.7	42
167	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	3.5	42
168	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 79.	17.0	42
169	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 683-688.	2.4	42
170	Allogeneic hematopoietic cell transplantation for metastatic breast cancer. <i>Bone Marrow Transplantation</i> , 2008, 41, 537-545.	2.4	41
171	Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. <i>Experimental Hematology</i> , 2012, 40, 521-527.	0.4	41
172	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <i>Bone Marrow Transplantation</i> , 2014, 49, 1475-1480.	2.4	41
173	Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. <i>Haematologica</i> , 2014, 99, 535-540.	3.5	41
174	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group – an observational analysis by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2015, 50, 1063-1068.	2.4	41
175	Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 2212-2220.	1.6	41
176	Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Haematologica</i> , 2013, 98, 1467-1475.	3.5	40
177	Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 370-374.	2.0	40
178	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	1.8	40
179	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 1066-1074.	3.5	40
180	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	4.1	40

#	ARTICLE	IF	CITATIONS
181	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020, 26, 6475-6482.	7.0	40
182	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 26.	6.2	40
183	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , 2018, 9, 3379-3393.	1.8	40
184	Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukocytapheresis and bone marrow harvest. <i>Bone Marrow Transplantation</i> , 1995, 16, 541-7.	2.4	40
185	Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2005, 105, 405-409.	1.4	39
186	Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 30-36.	0.9	39
187	High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 2015, 56, 3295-3300.	1.3	39
188	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1599-1601.	2.4	39
189	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1449-1454.	2.0	39
190	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 751-757.	2.0	39
191	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 88.	6.2	39
192	Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2006, 37, 183-189.	2.4	38
193	Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe FranÃ§aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2014, 49, 756-760.	2.4	38
194	Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. <i>Bone Marrow Transplantation</i> , 1990, 5, 7-12.	2.4	38
195	Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du MyÃ©lome (IFM) and the SociÃ©tÃ© FranÃ§aise de Greffe de Moelle et ThÃ©rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2005, 35, 165-169.	2.4	37
196	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <i>OncImmunology</i> , 2017, 6, e1307491.	4.6	37
197	Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 209-215.	2.4	37
198	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	2.4	37

#	ARTICLE	IF	CITATIONS
199	CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2004, 32, 1097-1102.	0.4	36
200	Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. <i>Experimental Hematology</i> , 2010, 38, 1241-1250.	0.4	36
201	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 683-689.	3.5	36
202	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. <i>Leukemia</i> , 2019, 33, 230-239.	7.2	36
203	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	2.4	36
204	Pulmonary function changes 100 days and one year after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1993, 12, 457-61.	2.4	36
205	Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 1000-1005.	2.4	35
206	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. <i>Haematologica</i> , 2014, 99, 1762-1768.	3.5	35
207	Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 549-554.	2.0	35
208	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , 2018, 2, 1180-1186.	5.2	35
209	The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. <i>Annals of Hematology</i> , 2019, 98, 1755-1763.	1.8	35
210	Discrete early pro-B and pre-B stages in normal human bone marrow as defined by surface pseudo-light chain expression. <i>European Journal of Immunology</i> , 1994, 24, 257-264.	2.9	34
211	High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. <i>Bone Marrow Transplantation</i> , 1998, 21, 249-254.	2.4	34
212	Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 527-530.	2.4	34
213	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	2.4	34
214	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	5.2	34
215	Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. <i>Bone Marrow Transplantation</i> , 1996, 17, 533-6.	2.4	34
216	Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2003, 32, 993-999.	2.4	33

#	ARTICLE	IF	CITATIONS
217	Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: Long-term prospective multicenter study. <i>Experimental Hematology</i> , 2013, 41, 127-133.	0.4	33
218	Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2014, 49, 1170-1175.	2.4	33
219	Allogeneic hematopoietic stem cell transplantation for <sc>T</sc>â€prolymphocytic leukemia: a report from the <sc>F</sc>rench society for stem cell transplantation (<sc>SFGM</sc>â€<sc>TC</sc>). <i>European Journal of Haematology</i> , 2015, 94, 265-269.	2.2	33
220	Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. <i>Journal of Hematology and Oncology</i> , 2017, 10, 31.	17.0	33
221	Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. <i>Blood</i> , 2001, 97, 2580-2586.	1.4	32
222	Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. <i>Bone Marrow Transplantation</i> , 2016, 51, 319-321.	2.4	32
223	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remissionâ€Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer</i> , 2017, 123, 824-831.	4.1	32
224	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. <i>Clinical Cancer Research</i> , 2018, 24, 2794-2803.	7.0	32
225	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. <i>Bone Marrow Transplantation</i> , 2000, 25, 1053-1058.	2.4	31
226	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. <i>Cancer</i> , 2015, 121, 1809-1816.	4.1	31
227	Longâ€term followâ€up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	4.1	31
228	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2016, 51, 1184-1190.	2.4	31
229	Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cellâ€Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 240-247.	2.0	31
230	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017, 52, 689-696.	2.4	31
231	Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Sociâ€tâ€ Francophone de Greffe de Moelle et de Thâ€rapie Cellulaire (SFGM-TC). <i>Journal of Hematology and Oncology</i> , 2020, 13, 56.	17.0	31
232	Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Haematologica</i> , 2006, 91, 1438-40.	3.5	31
233	Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. <i>Bone Marrow Transplantation</i> , 2004, 33, 913-920.	2.4	30
234	Impact of postremission consolidation chemotherapy on outcome after reducedâ€intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2014, 120, 855-863.	4.1	30

#	ARTICLE	IF	CITATIONS
235	Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit. <i>Journal of Critical Care</i> , 2015, 30, 1107-1113.	2.2	30
236	Manufacturing Natural Killer Cells as Medicinal Products. <i>Frontiers in Immunology</i> , 2016, 7, 504.	4.8	30
237	Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. <i>Blood</i> , 2017, 130, 2186-2195.	1.4	30
238	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	4.1	30
239	Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2019, 54, 1586-1594.	2.4	30
240	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	5.2	30
241	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.8	30
242	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	7.2	30
243	Second Neoplasms Following High-dose Chemotherapy and Autologous Stem Cell Transplantation for Malignant Lymphomas: A Report of Six Cases in a Cohort of 171 Patients from a Single Institution. <i>Leukemia and Lymphoma</i> , 1998, 31, 187-194.	1.3	29
244	Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. <i>Bone Marrow Transplantation</i> , 2004, 33, 839-846.	2.4	29
245	Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. <i>Leukemia</i> , 2010, 24, 467-469.	7.2	29
246	Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT. <i>Annals of Oncology</i> , 2016, 27, 1088-1094.	1.2	29
247	Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 592-599.	2.4	29
248	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	2.4	29
249	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
250	Patient Condition Affects the Collection of Peripheral Blood Progenitors After Priming with Recombinant Granulocyte Colony-Stimulating Factor. <i>Stem Cells and Development</i> , 1995, 4, 171-179.	1.0	28
251	Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>Haematologica</i> , 2010, 95, 950-955.	3.5	28
252	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. <i>Haematologica</i> , 2015, 100, 269-274.	3.5	28

#	ARTICLE	IF	CITATIONS
253	Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial. <i>Cancer</i> , 2015, 121, 562-569.	4.1	28
254	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	7.0	28
255	Haploidentical transplant in patients with myelodysplastic syndrome. <i>Blood Advances</i> , 2017, 1, 1876-1883.	5.2	28
256	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 859-866.	4.1	28
257	Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. <i>Bone Marrow Transplantation</i> , 1991, 8, 105-11.	2.4	28
258	Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001, 27, 167-175.	2.4	27
259	National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. <i>Leukemia and Lymphoma</i> , 2014, 55, 1106-1112.	1.3	27
260	Second allogeneic stem cell transplant for aplastic anaemia: a retrospective study by the severe aplastic anaemia working party of the European society for blood and marrow transplantation. <i>British Journal of Haematology</i> , 2015, 171, 606-614.	2.5	27
261	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (<sc>ALWP</sc>) of the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2018, 183, 411-420.	2.5	27
262	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
263	Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2012, 87, 1074-1078.	4.1	26
264	Neutropenic cancer patients with severe sepsis: need for antibiotics in the first hour. <i>Intensive Care Medicine</i> , 2014, 40, 1173-1174.	8.2	26
265	Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 209-218.	4.1	26
266	Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 1997, 19, 875-881.	2.4	25
267	Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. <i>British Journal of Dermatology</i> , 2002, 147, 433-441.	1.5	25
268	Double umbilical cord blood transplantation for hematological malignancies: A long-term analysis from the SFGM-TC registry. <i>Experimental Hematology</i> , 2013, 41, 924-933.	0.4	25
269	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 238-242.	2.4	25
270	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <i>Haematologica</i> , 2014, 99, 1486-1491.	3.5	25

#	ARTICLE	IF	CITATIONS
271	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. <i>American Journal of Hematology</i> , 2014, 89, 83-87.	4.1	25
272	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1549-1554.	2.0	25
273	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1987-1994.	2.4	25
274	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. <i>Leukemia</i> , 2020, 34, 87-99.	7.2	25
275	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021, 109, 1071-1088.	3.3	25
276	Do different conditioning regimens really make a difference?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 237-245.	2.5	25
277	Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities. <i>Bone Marrow Transplantation</i> , 1993, 12, 583-9.	2.4	25
278	Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: a report from the Groupe d'Etude des Greffes de Moelle Osseuse.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1865-1869.	1.6	24
279	Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 165-170.	2.4	24
280	Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 704-710.	0.4	24
281	Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2508-2513.	1.3	24
282	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2015, 6, 564.	4.8	24
283	Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the Soci�t� Francaise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1059-1067.	2.0	24
284	Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. <i>Bone Marrow Transplantation</i> , 2016, 51, 418-423.	2.4	24
285	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 422-430.	2.4	24
286	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.. <i>Blood</i> , 2009, 114, 663-663.	1.4	24
287	Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. <i>Bone Marrow Transplantation</i> , 1994, 14, 383-8.	2.4	24
288	High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. <i>British Journal of Cancer</i> , 1998, 78, 913-921.	6.4	23

#	ARTICLE	IF	CITATIONS
289	CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. <i>Bone Marrow Transplantation</i> , 1999, 23, 387-394.	2.4	23
290	Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. <i>Bone Marrow Transplantation</i> , 2006, 37, 709-710.	2.4	23
291	Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Leukemia Research</i> , 2015, 39, 933-937.	0.8	23
292	The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016, 51, 1134-1136.	2.4	23
293	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 620-621.	2.4	23
294	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. <i>British Journal of Haematology</i> , 2018, 181, 86-96.	2.5	23
295	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1944-1952.	7.2	23
296	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e204-e208.	2.0	23
297	Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 617-623.	0.4	23
298	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2015, 126, 863-863.	1.4	23
299	Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III/IV acute graft-versus-host disease. <i>Transplant International</i> , 1991, 4, 3-7.	1.6	22
300	Long-term follow-up of T-cell depletion for bone marrow transplantation. <i>Lancet, The</i> , 1993, 341, 51-52.	13.7	22
301	Rescue of haemopoiesis by a combination of growth factors including stem-cell factor. <i>Lancet, The</i> , 2000, 356, 1325-1326.	13.7	22
302	Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. <i>British Journal of Haematology</i> , 2001, 114, 698-700.	2.5	22
303	Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation. <i>Blood</i> , 2002, 100, 1484-1489.	1.4	22
304	Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Leukemia</i> , 2003, 17, 811-813.	7.2	22
305	Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. <i>Bone Marrow Transplantation</i> , 2012, 47, 1442-1447.	2.4	22
306	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2016, 51, 194-198.	2.4	22

#	ARTICLE	IF	CITATIONS
307	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. <i>American Journal of Hematology</i> , 2018, 93, 769-777.	4.1	22
308	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	17.0	22
309	Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. <i>Blood</i> , 2009, 113, 1868-1869.	1.4	21
310	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 128.	17.0	21
311	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€TD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 736-744.	4.1	21
312	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 86-93.	2.0	21
313	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 1242-1249.	5.2	21
314	A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021, 138, 740-740.	1.4	21
315	Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia. <i>Blood</i> , 1997, 89, 2222-3.	1.4	21
316	Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. <i>Experimental Hematology</i> , 2003, 31, 873-880.	0.4	20
317	Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. <i>Leukemia</i> , 2003, 17, 1596-1599.	7.2	20
318	Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. <i>European Journal of Haematology</i> , 2012, 89, 206-213.	2.2	20
319	Planctomycetes DNA in Febrile Aplastic Patients with Leukemia, Rash, Diarrhea, and Micronodular Pneumonia. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3453-3455.	3.9	20
320	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1372-1378.	2.0	20
321	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cellâ€Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1803-1809.	2.0	20
322	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1067-1076.	2.4	20
323	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
324	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma â€ a LWPâ€EBMT study. <i>British Journal of Haematology</i> , 2020, 188, 745-756.	2.5	20

#	ARTICLE	IF	CITATIONS
325	Reduced Intensity Conditioning Regimen in Single Unrelated Cord Blood Transplantation in Adults with Hematological Malignant Disorders. An Eurocord-Netcord and SFGM-TC Survey.. Blood, 2006, 108, 3143-3143.	1.4	20
326	Fractionated or single-dose total body irradiation in 171 acute myeloblastic leukemias in first complete remission: Is there a best choice?1. International Journal of Radiation Oncology Biology Physics, 1995, 31, 509-517.	0.8	19
327	High-Dose Therapy and Autologous Bone Marrow Transplantation in First Complete or Partial Remission for Poor Prognosis Hodgkin's Disease. Leukemia and Lymphoma, 1996, 20, 259-266.	1.3	19
328	Improved outcome of patients with low and intermediate risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. Cancer, 2011, 117, 974-981.	4.1	19
329	Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Experimental Hematology, 2013, 41, 1008-1015.	0.4	19
330	Long term outcome after allogeneic stem cell transplantation with reduced intensity conditioning in patients with multiple myeloma. American Journal of Hematology, 2013, 88, 370-374.	4.1	19
331	Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Transplantation, 2015, 99, 1672-1680.	1.0	19
332	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. Journal of Internal Medicine, 2018, 283, 371-379.	6.0	19
333	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. Bone Marrow Transplantation, 2019, 54, 1730-1737.	2.4	19
334	Do different conditioning regimens really make a difference?. Hematology American Society of Hematology Education Program, 2012, 2012, 237-45.	2.5	19
335	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. Blood, 2018, 132, 818-818.	1.4	19
336	Impact of Prior Invasive Pulmonary Aspergillosis (IPA) on Outcome in Patients Receiving Reduced Intensity Conditioning (RIC) Allogeneic Haematopoietic Stem Cell Transplantation (Allo-SCT).. Blood, 2008, 112, 1147-1147.	1.4	19
337	Immune reconstitution after blood cell transplantation. Hematology and Cell Therapy, 1997, 39, 261-264.	0.7	18
338	Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation. Leukemia, 2002, 16, 2259-2266.	7.2	18
339	Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Experimental Hematology, 2011, 39, 892-896.	0.4	18
340	Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2014, 49, 671-678.	2.4	18
341	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. American Journal of Hematology, 2017, 92, 653-659.	4.1	18
342	Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. American Journal of Hematology, 2017, 92, 344-350.	4.1	18

#	ARTICLE	IF	CITATIONS
343	Anti- $\text{CD}20$ antibody improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2018, 124, 2523-2533.	4.1	18
344	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3-ITD : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	3.5	18
345	Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. <i>Bone Marrow Transplantation</i> , 2018, 53, 1096-1104.	2.4	18
346	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>American Journal of Hematology</i> , 2018, 93, 416-423.	4.1	18
347	Sarcopenic obesity derived from PET/CT predicts mortality in lymphoma patients undergoing hematopoietic stem cell transplantation. <i>Current Research in Translational Medicine</i> , 2019, 67, 93-99.	1.8	18
348	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 349-355.	2.4	18
349	$\text{CD}34^+$ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2020, 95, 892-899.	4.1	18
350	Post-transplantation cyclophosphamide GVHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. <i>Leukemia</i> , 2021, 35, 585-594.	7.2	18
351	Allogeneic Stem Cell Transplantation (SCT) with Non Myeloablative Conditioning Regimen (NST) Following Intensive Consolidation May Be Equivalent to Conventional alloSCT and Superior to autoSCT for Patients over 50 with Acute Myeloid Leukemia (AML) in 1stCR: First Results of the AML 2001 Trial. <i>Blood</i> , 2006, 108, 319-319.	1.4	18
352	In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: Results of a phase I trial. <i>Stem Cells</i> , 1994, 12, 322-328.	3.2	17
353	Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1472-1477.	2.4	17
354	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. <i>American Journal of Hematology</i> , 2017, 92, 789-796.	4.1	17
355	Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with posttransplantation cyclophosphamide in older patients. <i>British Journal of Haematology</i> , 2017, 176, 132-135.	2.5	17
356	Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1295-1303.	2.4	17
357	Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of $\text{CD}3^+$ cells. <i>British Journal of Haematology</i> , 2019, 185, 570-573.	2.5	17
358	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3566-3573.	4.1	17
359	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. <i>Cancer</i> , 2019, 125, 1499-1506.	4.1	17
360	Single-Unit versus Double-Unit Umbilical Cord Blood Transplantation in Children and Young Adults with Residual Leukemic Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 734-742.	2.0	17

#	ARTICLE	IF	CITATIONS
361	Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1723-1730.	3.5	17
362	Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. <i>American Journal of Hematology</i> , 2021, 96, 80-88.	4.1	17
363	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated <i>versus</i> T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
364	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <sc>EBMT</sc> and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	4.1	17
365	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL). <i>Blood</i> , 2013, 122, 552-552.	1.4	17
366	Lenalidomide as Salvage Therapy after Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2008, 112, 3704-3704.	1.4	17
367	A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. <i>Bone Marrow Transplantation</i> , 1996, 18, 495-9.	2.4	17
368	Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. <i>Journal of Leukocyte Biology</i> , 2002, 72, 939-45.	3.3	17
369	Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report. <i>Bone Marrow Transplantation</i> , 2001, 28, 1157-1160.	2.4	16
370	Blood versus marrow hematopoietic allogeneic graft. <i>Transfusion and Apheresis Science</i> , 2003, 29, 53-59.	1.0	16
371	Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2005, 35, 37-43.	2.4	16
372	Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 167-173.	0.9	16
373	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2010, 38, 55-60.	0.4	16
374	Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. <i>Annals of Hematology</i> , 2012, 91, 1289-1297.	1.8	16
375	In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?. <i>Bone Marrow Transplantation</i> , 2015, 50, 1411-1415.	2.4	16
376	Prognostic significance of myelodysplasia-related changes according to the <sc>WHO</sc> classification among <sc>ELN</sc> intermediate-risk <sc>AML</sc> patients. <i>American Journal of Hematology</i> , 2015, 90, E22-4.	4.1	16
377	Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. <i>Seminars in Hematology</i> , 2016, 53, 111-114.	3.4	16
378	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2251-2260.	2.0	16

#	ARTICLE	IF	CITATIONS
379	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1798-1802.	2.0	16
380	Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. <i>American Journal of Hematology</i> , 2019, 94, 431-438.	4.1	16
381	Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. <i>American Journal of Hematology</i> , 2019, 94, 80-86.	4.1	16
382	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	5.2	16
383	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	2.4	16
384	A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 21, 107-114.	1.3	15
385	Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. <i>Bone Marrow Transplantation</i> , 1998, 22, 1153-1158.	2.4	15
386	Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 901-906.	2.4	15
387	Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2013, 48, 249-252.	2.4	15
388	Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2014, 49, 361-365.	2.4	15
389	Hematopoietic stem cell transplantation for adult patients with isolated <i>NPM1</i> mutated acute myeloid leukemia in first remission. <i>American Journal of Hematology</i> , 2019, 94, 231-239.	4.1	15
390	Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1810-1817.	2.0	15
391	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , 2019, 125, 90-98.	4.1	15
392	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
393	Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry. <i>Blood</i> , 2020, 136, 15-16.	1.4	15
394	Liquid culture and cryopreservation of marrow cells of leukaemic patients prior to autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1989, 72, 519-523.	2.5	14
395	CD34+ immunoselected cells for poor graft function following allogeneic BMT. <i>Cytotherapy</i> , 2000, 2, 367-370.	0.7	14
396	The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. <i>British Journal of Haematology</i> , 2002, 118, 762-770.	2.5	14

#	ARTICLE	IF	CITATIONS
397	Long-term graft-versus-Waldenström macroglobulinemia effect following reduced intensity conditioning allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 175-177.	2.4	14
398	Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. <i>Haematologica</i> , 2008, 93, 834-841.	3.5	14
399	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 255-263.	2.4	14
400	Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2020, 126, 1004-1015.	4.1	14
401	Impact of total body irradiation vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1200-1208.	4.1	14
402	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. <i>Blood Advances</i> , 2022, 6, 1804-1812.	5.2	14
403	Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma?: a Retrospective Study From the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2010, 116, 688-688.	1.4	14
404	A case of segmental macular neurofibromatosis.. <i>Acta Dermato-Venereologica</i> , 1994, 74, 329.	1.3	14
405	Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients. <i>Leukemia</i> , 1999, 13, 950-956.	7.2	13
406	Allogeneic stem cell transplantation for renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 901-911.	2.4	13
407	Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2012, 88, 497-503.	2.2	13
408	Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. <i>Cancer Medicine</i> , 2016, 5, 3068-3076.	2.8	13
409	Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. <i>Annals of Hematology</i> , 2020, 99, 1855-1862.	1.8	13
410	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1305-1315.	2.4	13
411	Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1994, 13, 541-7.	2.4	13
412	Fractionated total body irradiation and allogeneic bone marrow transplantation for standard risk leukemia. <i>Radiotherapy and Oncology</i> , 1989, 16, 289-295.	0.6	12
413	Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. <i>Bone Marrow Transplantation</i> , 2000, 25, 35-40.	2.4	12
414	Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution. <i>Bone Marrow Transplantation</i> , 2004, 33, 177-182.	2.4	12

#	ARTICLE	IF	CITATIONS
415	One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. <i>British Journal of Haematology</i> , 2005, 129, 403-410.	2.5	12
416	Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution. <i>Leukemia and Lymphoma</i> , 2013, 54, 2392-2398.	1.3	12
417	Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. <i>Leukemia and Lymphoma</i> , 2013, 54, 1538-1540.	1.3	12
418	Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning. <i>Leukemia</i> , 2013, 27, 2113-2117.	7.2	12
419	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. <i>Haematologica</i> , 2016, 101, e34-e37.	3.5	12
420	The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2017, 52, 135-137.	2.4	12
421	Reduced Relapse Incidence with FLAMSAâ€œRIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2224-2232.	2.0	12
422	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	3.5	12
423	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020, 20, 1140.	2.6	12
424	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 76.	17.0	12
425	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Cancers</i> , 2021, 13, 2673.	3.7	12
426	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	7.0	12
427	Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. <i>Blood</i> , 1990, 76, 1092-7.	1.4	12
428	Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. <i>British Journal of Cancer</i> , 1992, 65, 399-404.	6.4	11
429	Interleukin 2 in the treatment of acute leukemia. <i>Leukemia Research</i> , 1998, 22, 1165-1170.	0.8	11
430	Myelodysplastic features developing in Philadelphia-negative cells during imatinib mesylate therapy for CML: report of a new case. <i>Leukemia</i> , 2003, 17, 1901-1902.	7.2	11
431	Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related or Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1560-1565.	2.0	11
432	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societ� Fran�saise de Greffe de Moelle et Therapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1515-1523.	2.0	11

#	ARTICLE	IF	CITATIONS
433	Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>Annals of Oncology</i> , 2017, 28, 2191-2198.	1.2	11
434	Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?. <i>Blood</i> , 2017, 129, 1227-1230.	1.4	11
435	Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1657-1663.	2.0	11
436	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 930-936.	2.0	11
437	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. <i>Bone Marrow Transplantation</i> , 2020, 55, 224-232.	2.4	11
438	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2454-2463.	2.4	11
439	Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2011, 118, 2008-2008.	1.4	11
440	Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.. <i>Blood</i> , 2004, 104, 619-619.	1.4	11
441	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 3359-3359.	1.4	11
442	Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study. <i>Bone Marrow Transplantation</i> , 1991, 8, 259-64.	2.4	11
443	Long-term side-effects in children receiving allogeneic bone marrow transplantation in first complete remission of acute leukaemia. <i>Bone Marrow Transplantation</i> , 1995, 15, 337-41.	2.4	11
444	Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 587.e1-587.e7.	1.2	11
445	Outcome of Adult Patients with Acute Myeloid Leukemia who Failed to Achieve Complete Remission after one Course of Induction Chemotherapy: A Report from the BGMT Study Group: For the BGMT. <i>Leukemia and Lymphoma</i> , 2001, 42, 57-65.	1.3	10
446	High-Dose Chemotherapy with Blood or Bone Marrow Transplants for Rhabdomyosarcoma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 525-532.	2.0	10
447	Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <i>Haematologica</i> , 2012, 97, 482-490.	3.5	10
448	Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience. <i>Experimental Hematology</i> , 2013, 41, 17-27.	0.4	10
449	Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. <i>Bone Marrow Transplantation</i> , 2015, 50, 865-867.	2.4	10
450	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto�SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>European Journal of Haematology</i> , 2015, 94, 449-455.	2.2	10

#	ARTICLE	IF	CITATIONS
451	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
452	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
453	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 414-423.	3.5	10
454	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. <i>Bone Marrow Transplantation</i> , 2021, 56, 883-889.	2.4	10
455	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	2.4	10
456	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
457	Reduced Intensity Conditioning Regimen for Unrelated Cord Blood Transplantation in Adults. A Multicentric Phase I-II Trial.. <i>Blood</i> , 2005, 106, 3658-3658.	1.4	10
458	Allogeneic Stem Cell Transplantation (allo-SCT) for Adult Patients with Active Refractory/Relapsed Hematological Malignancies: a Survey From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).. <i>Blood</i> , 2010, 116, 3456-3456.	1.4	10
459	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. <i>Bone Marrow Transplantation</i> , 2022, 57, 384-390.	2.4	10
460	Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation. <i>Leukemia</i> , 2005, 19, 500-503.	7.2	9
461	Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL. <i>Leukemia and Lymphoma</i> , 2009, 50, 485-487.	1.3	9
462	Allogeneic hematopoietic stem cell transplantation in ovarian cancer "the EBMT experience. <i>International Journal of Cancer</i> , 2010, 127, 1446-1452.	5.1	9
463	Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 1564-1568.	2.4	9
464	90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. <i>Annals of Oncology</i> , 2015, 26, 193-198.	1.2	9
465	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers "On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2098-2104.	2.0	9
466	Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. <i>Bone Marrow Transplantation</i> , 2020, 55, 1367-1378.	2.4	9
467	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 622-634.	2.4	9
468	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021, 195, 417-428.	2.5	9

#	ARTICLE	IF	CITATIONS
469	Impact of donor-derived CD34 ⁺ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 261-270.	2.4	9
470	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. <i>British Journal of Haematology</i> , 2022, 197, 82-96.	2.5	9
471	Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): Final analysis of survival in two consecutive ISC trials. <i>Annals of Oncology</i> , 2001, 12, 513-517.	1.2	8
472	Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells. <i>Bone Marrow Transplantation</i> , 2004, 33, 1209-1214.	2.4	8
473	Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. <i>British Journal of Haematology</i> , 2006, 135, 408-410.	2.5	8
474	Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. <i>Bone Marrow Transplantation</i> , 2008, 42, 689-691.	2.4	8
475	Parvovirus B19 as an etiological agent of acute pleuro-pericarditis. <i>Bone Marrow Transplantation</i> , 2011, 46, 317-318.	2.4	8
476	Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 2063-2065.	1.3	8
477	Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 250-256.	2.0	8
478	Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. <i>Bone Marrow Transplantation</i> , 2015, 50, 1586-1588.	2.4	8
479	Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC). <i>Haematologica</i> , 2016, 101, e262-e265.	3.5	8
480	Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 241-242.	0.4	8
481	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 213-218.	2.4	8
482	Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes. <i>Bone Marrow Transplantation</i> , 2019, 54, 458-464.	2.4	8
483	The impact of counseling on nutritional status among hematopoietic stem cell recipients: results of a randomized controlled trial. <i>Bone Marrow Transplantation</i> , 2019, 54, 752-756.	2.4	8
484	Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation. <i>Journal of Medical Virology</i> , 2020, 92, 3665-3673.	5.0	8
485	Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	2.4	8
486	Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. <i>Cytotherapy</i> , 2021, 23, 483-487.	0.7	8

#	ARTICLE	IF	CITATIONS
487	EARLY ESTABLISHMENT OF CHIMERISM IN THE B AND T LYMPHOID LINEAGES AFTER TRANSPLANTATION OF ALLOGENEIC MOBILIZED BLOOD CELLS IN LEUKEMIC PATIENTS ¹ . <i>Transplantation</i> , 1997, 63, 1646-1652.	1.0	8
488	Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe FranciSaise De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML. <i>Blood</i> , 2010, 116, 2266-2266.	1.4	8
489	Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD. <i>Bone Marrow Transplantation</i> , 1999, 24, 225-227.	2.4	7
490	Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL. <i>Bone Marrow Transplantation</i> , 2003, 32, 961-963.	2.4	7
491	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. <i>Leukemia and Lymphoma</i> , 2012, 53, 2186-2191.	1.3	7
492	Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2211-2212.	1.3	7
493	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015, 100, e423-e427.	3.5	7
494	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 475-481.	2.0	7
495	Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the SociA©tA© FranA§aise de Greffe de Moelle et de ThA©rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2016, 51, 358-364.	2.4	7
496	T-cell-replete haploidentical transplantation in acute myeloid leukemia. <i>Experimental Hematology</i> , 2018, 58, 5-16.	0.4	7
497	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019, 54, 1164-1167.	2.4	7
498	Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Clinical Rheumatology</i> , 2019, 38, 1501-1511.	2.2	7
499	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 282-294.	4.1	7
500	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	2.2	7
501	Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 659-664.	2.0	7
502	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	2.4	7
503	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 655-663.	2.4	7
504	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , 2021, 10, 23-33.	2.8	7

#	ARTICLE	IF	CITATIONS
505	Related versus unrelated allogeneic HPC graft cryopreservation: a single-center experience in the context of the global COVID-19 pandemic. <i>Bone Marrow Transplantation</i> , 2021, 56, 2013-2015.	2.4	7
506	Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2166-2166.	1.4	7
507	Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers. <i>Blood</i> , 2014, 124, 2554-2554.	1.4	7
508	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. <i>Blood</i> , 2016, 128, 1165-1165.	1.4	7
509	Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 678-678.	1.4	7
510	Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).. <i>Blood</i> , 2006, 108, 2850-2850.	1.4	7
511	A Direct Comparison of High Dose Cytarabine to Combination of Gemtuzumab and High Dose Cytarabine for Acute Myeloid Leukemia Patients in First Relapse Confirmed the Benefit of Gemtuzumab Based Regimens.. <i>Blood</i> , 2009, 114, 2051-2051.	1.4	7
512	Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus On Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4496-4496.	1.4	7
513	Phase II Prospective Multicentre Study Testing The Efficacy and Safety Of a Clofarabine (Clo), I.v. Busulfan (Bu) and Antithymocyte Globulins (ATG)-Based Reduced-Intensity Conditioning Regimen (RIC) Before Allogeneic Stem Cell Transplantation (allo-SCT) For High-Risk Myelodysplastic Syndrome Or Acute Leukemia: The Cloric Trial. <i>Blood</i> , 2013, 122, 413-413.	1.4	7
514	Measurable residual disease, FLT3â€”TD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1â€”mutated acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 1068-1080.	2.8	7
515	Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission. <i>Bone Marrow Transplantation</i> , 1988, 3, 105-11.	2.4	7
516	Reconstitution of human immunoglobulin VH repertoire after bone marrow transplantation mimics B-cell ontogeny. <i>Blood</i> , 1993, 81, 3153-7.	1.4	7
517	Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers. <i>Anticancer Research</i> , 2000, 20, 3987-91.	1.1	7
518	Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 169.e1-169.e9.	1.2	7
519	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1421-1427.	2.4	7
520	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 710.e1-710.e10.	1.2	7
521	Direct evidence for dissociated megakaryocytic chimaerism in a Wiskottâ€”Aldrich patient successfully allografted. <i>British Journal of Haematology</i> , 1995, 90, 336-340.	2.5	6
522	Constitutional Balanced Pericentric Inversions of Chromosomes X, 2, and 5 in Myeloid Malignancies. <i>Cancer Genetics and Cytogenetics</i> , 1998, 107, 28-31.	1.0	6

#	ARTICLE	IF	CITATIONS
523	OPTIMIZATION OF PERIPHERAL BLOOD STEM CELL COLLECTION BY LEUKOPHERESIS. <i>International Journal of Technology Assessment in Health Care</i> , 1999, 15, 161-172.	0.5	6
524	Ex vivo expansion of human hematopoietic progenitors and cells to support high-dose chemoradiation therapy: Five years of clinical experience. <i>Cytokines, Cellular & Molecular Therapy</i> , 2000, 6, 97-108.	0.3	6
525	rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells. <i>Bone Marrow Transplantation</i> , 2005, 35, 25-32.	2.4	6
526	TLI in refractory chronic GVHD. <i>Bone Marrow Transplantation</i> , 2013, 48, 854-858.	2.4	6
527	Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 794-798.	2.4	6
528	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 1849-1853.	1.3	6
529	Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2015, 50, 253-258.	2.4	6
530	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016, 51, 462-465.	2.4	6
531	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	2.4	6
532	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	2.4	6
533	Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome. <i>Annals of Hematology</i> , 2020, 99, 773-780.	1.8	6
534	Vitamins and minerals intake adequacy in hematopoietic stem cell transplant: results of a randomized controlled trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1106-1115.	2.4	6
535	Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 999.e1-999.e10.	1.2	6
536	First Line Therapy with Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete Remission.. <i>Blood</i> , 2004, 104, 101-101.	1.4	6
537	A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.. <i>Blood</i> , 2009, 114, 632-632.	1.4	6
538	Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning Regimen. <i>Blood</i> , 2012, 120, 232-232.	1.4	6
539	Comparison Of Umbilical Cord Blood and Haploidentical Donor Grafts In Adults With High Risk Hematologic Diseases After Fludarabine Cyclophosphamide and TBI 2 Gy Based Reduced-Intensity Conditioning Regimen Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3288-3288.	1.4	6
540	Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 729-729.	1.4	6

#	ARTICLE	IF	CITATIONS
541	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>Oncotarget</i> , 2018, 9, 36603-36612.	1.8	6
542	The Impact of Center Experience on Results of Reduced Intensity " Allogeneic Hematopoietic Stem Cell Transplantation. A Survey From the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 3517-3517.	1.4	6
543	Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1995, 16, 199-200.	2.4	6
544	Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2. <i>Leukemia</i> , 1994, 8, 1230-5.	7.2	6
545	The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. <i>Leukemia</i> , 2022, 36, 1646-1653.	7.2	6
546	Transient detection of β -galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy. <i>Experimental Hematology</i> , 2002, 30, 108-115.	0.4	5
547	Early allogeneic stem cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat analysis of the long-term experience of the BGMT group. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 17-18.	2.0	5
548	Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 142, 848-850.	2.5	5
549	Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1630-1632.	1.3	5
550	First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: Significant impact on different outcomes. <i>Experimental Hematology</i> , 2014, 42, 161-162.	0.4	5
551	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2014, 49, 950-954.	2.4	5
552	REBOUND "Trained to live again" The practice of great Olympic coaches improves and enhances the quality of life of cancer patients in remission after hematopoietic stem cell allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 997-999.	2.4	5
553	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/Cell lymphoma, nasal type: A French study from the Soci� Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	4.1	5
554	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	2.4	5
555	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	1.4	5
556	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2005, 106, 659-659.	1.4	5
557	Impact of Postremission Consolidation Chemotherapy On Outcome After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for AML in First Complete Remission (CR1): A Report From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2012, 120, 3098-3098.	1.4	5
558	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2012, 120, 1975-1975.	1.4	5

#	ARTICLE	IF	CITATIONS
559	Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT. <i>Blood</i> , 2013, 122, 542-542.	1.4	5
560	Allogeneic Stem Cell Transplantation (Allo-SCT) for De Novo Ph+ Acute Myeloid Leukemia: A Study from the French Society of Bone Marrow Transplantation and Cell Therapies. <i>Blood</i> , 2014, 124, 1232-1232.	1.4	5
561	Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 2899-2899.	1.4	5
562	Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 2280-2280.	1.4	5
563	Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Study. <i>Blood</i> , 2021, 138, 1817-1817.	1.4	5
564	Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. <i>European Cytokine Network</i> , 1991, 2, 231-7.	2.0	5
565	Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. <i>European Cytokine Network</i> , 1991, 2, 121-9.	2.0	5
566	Autologous bone marrow transplantation for B cell malignancies after in vitro purging with floating immunobeads. <i>Bone Marrow Transplantation</i> , 1990, 6, 301-7.	2.4	5
567	High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution. <i>Anticancer Research</i> , 1999, 19, 1455-61.	1.1	5
568	Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients 55 years of age. <i>American Journal of Hematology</i> , 2022, 97, 1065-1074.	4.1	5
569	Survey of Early Disappearance of BCR/ABL Fusion Transcript after Allogeneic or Autologous Stem Cell Transplantation for Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 42, 945-952.	1.3	4
570	Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1644-1646.	2.4	4
571	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100mg/m ² intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2315-2320.	1.3	4
572	Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimen. <i>American Journal of Hematology</i> , 2017, 92, E57-E59.	4.1	4
573	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. <i>Current Research in Translational Medicine</i> , 2019, 67, 8-15.	1.8	4
574	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <i>Journal of Internal Medicine</i> , 2019, 285, 446-454.	6.0	4
575	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2Gy) as conditioning prior to allogeneic stem cell transplantation in patients (>60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 729-739.	2.4	4
576	Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1642-1646.	2.4	4

#	ARTICLE	IF	CITATIONS
577	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2299-2305.	2.0	4
578	Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF. <i>PLoS ONE</i> , 2020, 15, e0228878.	2.5	4
579	Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 614-621.	2.4	4
580	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1077-1085.	2.4	4
581	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1842-1849.	2.4	4
582	Shwachman-Diamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29071.	1.5	4
583	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2018, 132, 708-708.	1.4	4
584	Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission: A Time-Dependent and Multistate Analysis from the French Innovative Leukemia Organization. <i>Blood</i> , 2018, 132, 209-209.	1.4	4
585	Lower Relapse and Better PFS Among Chemosensitive Patients Undergoing Allogeneic Transplantation By Haploidentical Compared With HLA-Identical DONOR: Results On A Cohort Of 94 Patients With Hodgkin's Lymphoma. <i>Blood</i> , 2013, 122, 2144-2144.	1.4	4
586	Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party. <i>Blood</i> , 2015, 126, 1210-1210.	1.4	4
587	Unrelated Cord Blood Transplantation after Reduced Intensity Conditioning (RIC) in Adults with Hematological Malignancy. An EBMT-Eurocord-Netcord, Societel-Française de Greffe de Moelle et de Thérapie Cellulaire and University of Minnesota Collaborative Study.. <i>Blood</i> , 2007, 110, 2027-2027.	1.4	4
588	ATG Dose Correlates with Acute and Chronic GvHD In Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation: A Large Retrospective Monocenter Analysis on 301 Patients.. <i>Blood</i> , 2010, 116, 3485-3485.	1.4	4
589	Efficacy and Safety of Micafungin for Prophylaxis of Invasive Fungal Infections in Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2012, 120, 4505-4505.	1.4	4
590	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	2.4	4
591	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	2.4	4
592	IN VIVO ADMINISTRATION OF RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR CORRECTS ACQUIRED NEUTROPHIL FUNCTION DEFICIENCY ASSOCIATION WITH CHRONIC GRAFT-VERSUS-HOST DISEASE. <i>British Journal of Haematology</i> , 1993, 83, 169-170.	2.5	3
593	Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2016, 57, 714-716.	1.3	3
594	Fatal acute respiratory distress syndrome with diffuse alveolar damage: donor lymphocyte infusion imputability?. <i>European Respiratory Journal</i> , 2016, 48, 1794-1796.	6.7	3

#	ARTICLE	IF	CITATIONS
595	Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 366-370.	2.4	3
596	Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S11.	2.0	3
597	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 613954.	4.8	3
598	The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute's Experience. <i>Clinical Hematology International</i> , 2021, 3, 119.	1.7	3
599	Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 2335-2338.	2.4	3
600	Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 3425-3425.	1.4	3
601	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4581-4581.	1.4	3
602	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. <i>Blood</i> , 2019, 134, 4575-4575.	1.4	3
603	Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years. <i>Blood</i> , 2020, 136, 9-10.	1.4	3
604	Updated Analysis of Hematopoietic Stem Cell Transplantations after Reduced Intensity Conditioning Regimen (RIC HSCT) for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry. <i>Blood</i> , 2005, 106, 45-45.	1.4	3
605	Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study. <i>Blood</i> , 2009, 114, 193-193.	1.4	3
606	Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged ≥60 Years: a Retrospective Study of 629 Patients From the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC). <i>Blood</i> , 2009, 114, 194-194.	1.4	3
607	Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). <i>Blood</i> , 2009, 114, 650-650.	1.4	3
608	Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial. <i>Blood</i> , 2012, 120, 1926-1926.	1.4	3
609	Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 2561-2561.	1.4	3
610	Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 664-664.	1.4	3
611	High Response Rate and Improved Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage Therapy after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Multiple Myeloma (MM). <i>Blood</i> , 2007, 110, 1080-1080.	1.4	3
612	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3211-3211.	1.4	3

#	ARTICLE	IF	CITATIONS
613	Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study. <i>Blood</i> , 2021, 138, 174-174.	1.4	3
614	Intensive immunotherapy with recombinant IL2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infections. <i>Bone Marrow Transplantation</i> , 1992, 10, 193-4.	2.4	3
615	Candida arthritis treated with intra-articular amphotericin B. <i>The European Journal of Medicine</i> , 1993, 2, 124-5.	0.1	3
616	Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement. <i>Hematology and Cell Therapy</i> , 1999, 41, 5-11.	0.7	2
617	<i>In vitro</i> inhibition of interleukin-2-induced defective polymorphonuclear chemotaxis by TNF inhibitor. <i>European Journal of Haematology</i> , 1993, 51, 13-17.	2.2	2
618	Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2010, 45, 1574-1575.	2.4	2
619	Impact of antithymocyte globulin on the need for platelet transfusions during reduced-intensity conditioning administration before allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2013, 41, 503-505.	0.4	2
620	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S242-S243.	2.0	2
621	S1622 TANDEM ALUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT. <i>HemaSphere</i> , 2019, 3, 749-750.	2.7	2
622	Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT. <i>Frontiers in Immunology</i> , 2020, 11, 1537.	4.8	2
623	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1047-1055.	2.4	2
624	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 461-469.	2.4	2
625	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 686-693.	0.4	2
626	A study of elite sport-inspired coaching for patients after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2755-2762.	2.4	2
627	Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Soci�t� Francophone de Greffe de Moelle et de Therapie Cellulaire. <i>Bone Marrow Transplantation</i> , 2021, 56, 2849-2856.	2.4	2
628	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019, 134, 324-324.	1.4	2
629	Overcoming the Negative Impact of Age Using Fludarabine-Based Conditioning Regimens for HLA-Identical Sibling HSCT in Patients with Severe Aplastic Anemia (SAA): A Study from the EBMT-SAA Working Party. <i>Blood</i> , 2006, 108, 3007-3007.	1.4	2
630	Unrelated Allogeneic Stem Cell Transplantation for Severe Acquired Aplastic Anemia: Has Outcome Improved?. <i>Blood</i> , 2006, 108, 3105-3105.	1.4	2

#	ARTICLE	IF	CITATIONS
631	Lenalidomide after Allogeneic Stem Cell Transplantation in Multiple Myeloma.. Blood, 2007, 110, 4840-4840.	1.4	2
632	Double Cord Blood Cell (CBC) Hematopoietic Stem Cell Transplantation after Standard or Reduced Intensity Conditioning: Report of the SFGMTC Registry.. Blood, 2008, 112, 1972-1972.	1.4	2
633	Phase II Prospective Multicenter Study of Treosulfan Based Reduced Intensity Conditioning In Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor. Blood, 2010, 116, 2353-2353.	1.4	2
634	Impact Of Rabbit Anti-Thymocyte Globulin-Containing Reduced-Intensity Conditioning Regimens On Outcomes Of Adults Undergoing Unrelated Cord Blood Transplantation For Hematological Malignancies. Blood, 2013, 122, 412-412.	1.4	2
635	Secondary Malignancies After Autologous Stem Cell Transplantation In Patients With Relapsed / Refractory Hodgkin's Lymphoma. A Retrospective Analysis On Behalf Of The Lymphoma Working Party Of The European Society For Blood and Marrow Transplantation (EBMT). Blood, 2013, 122, 4636-4636.	1.4	2
636	Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure. Blood, 2014, 124, 1228-1228.	1.4	2
637	Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT. Blood, 2014, 124, 187-187.	1.4	2
638	Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from		

#	ARTICLE	IF	CITATIONS
649	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 324-324.	1.4	2
650	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016, 128, 1169-1169.	1.4	2
651	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018, 132, 2143-2143.	1.4	2
652	A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2021, 138, 3937-3937.	1.4	2
653	Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation. <i>European Cytokine Network</i> , 1997, 8, 389-94.	2.0	2
654	T-cell depletion of allogeneic bone marrow grafts: enrichment of mononuclear cells using the COBE Spectra cell processor, followed by immunoselection of CD34(+) cells. <i>Cytotherapy</i> , 1999, 1, 469-77.	0.7	2
655	Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors. <i>Frontiers in Medicine</i> , 2022, 9, 820591.	2.6	2
656	Partial chimerism after T-cell-depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients: a cytogenetic documentation. <i>Blood</i> , 1988, 72, 89-93.	1.4	2
657	Response to Immunosuppressive Treatment Predicts Outcome in Patients with Chronic Graft-versus-Host Disease: A Single-Center Analysis of Longitudinal Data. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 576-583.	2.0	1
658	Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 417-420.	1.3	1
659	Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors. <i>Bone Marrow Transplantation</i> , 2014, 49, 1246-1247.	2.4	1
660	Comparison of Haploidentical T-Replete HSCT Followed with Post-Transplant High Dose Cyclophosphamide (PT-HDCy) with Matched Related (MRD) or Unrelated (UD) HSCT in Patients in or after the 6TH Decade. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S273-S274.	2.0	1
661	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e23.	0.4	1
662	T-Cell Replete Haploidentical Transplantation. , 2019, , 99-123.		1
663	PF747 DEFIBROTIDE TREATMENT IN ADULTS WITH SEVERE OR VERY SEVERE VENOâ€œCLCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE STUDY INTERIM RESULTS. <i>HemaSphere</i> , 2019, 3, 327-328.	2.7	1
664	Legionellosis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2555-2566.	2.4	1
665	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 831-840.	0.4	1
666	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWPâ€œEBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1563-1572.	2.4	1

#	ARTICLE	IF	CITATIONS
667	BONE MARROW AND BLOOD CELLS AS ALTERNATIVE SOURCES OF HEMATOPOIETIC PROGENITORS AFTER FAILURE OF A FIRST COLLECTION. <i>Transplantation</i> , 1996, 61, 518-522.	1.0	1
668	The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2018, 132, 3460-3460.	1.4	1
669	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 2038-2038.	1.4	1
670	Fludarabine and Busulfan-Based Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Transplantation (allo-SCT) with or without Anti-Thymocyte Globulin (ATG): Comparison between Two Prospective Studies in Patients with Myeloid Malignancies.. <i>Blood</i> , 2004, 104, 1241-1241.	1.4	1
671	Impact of HLA Allele Mismatch on the Outcome of Patients with Reduced-Intensity Allogeneic Haematopoietic Stem Cell Transplantation from Unrelated Donors: Analysis of 103 Patients of the French Registry.. <i>Blood</i> , 2006, 108, 3149-3149.	1.4	1
672	Cord Blood Transplantation from Unrelated Donors for Adults with Advanced Lymphoid Malignancies - A Eurocord-Netcord Group/EBMT-LWP Study.. <i>Blood</i> , 2007, 110, 2025-2025.	1.4	1
673	Cord Blood Transplantation after Non Myeloablative Conditioning (Minneapolis Protocol): Impact on Transplant Outcomes in 112 Adults with Hematologic Malignancy. A French Multicentric Study of the Societe' Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) and Eurocord.. <i>Blood</i> , 2007, 110, 2029-2029.	1.4	1
674	Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. <i>Blood</i> , 2008, 112, 2165-2165.	1.4	1
675	Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). <i>Blood</i> , 2008, 112, 345-345.	1.4	1
676	Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2009, 114, 1190-1190.	1.4	1
677	Interactions Between Total Nucleated and CD34 Cell Dose and Their Impact on Outcomes After Single and Double Unrelated Cord Blood Transplantation for Patients with Hematological Malignancies. An Analysis on Behalf of Societe' Francaise De Greffe De Moelle Et Therapie Cellulaire (SFGM-TC) and Eurocord. <i>Blood</i> , 2010, 116, 361-361.	1.4	1
678	Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2010, 116, 363-363.	1.4	1
679	Allogeneic Hematopoietic Stem Cell Transplantation in Paroxysmal Nocturnal Hemoglobinuria: A Transplant Versus No Transplant Matched Comparison Study On Behalf of the Severe Aplastic Anemia Working Party (SAA WP) of the European Group for Blood and Marrow Transplantation (EBMT) Group and the French Society of Hematology (SFH). <i>Blood</i> , 2011, 118, 2403-2403.	1.4	1
680	Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma: Comparative Analysis of Outcomes Between Unrelated and Related Donor. <i>Blood</i> , 2011, 118, 4513-4513.	1.4	1
681	Potential Synergic Effect of Lenalidomide-Rituximab Combination: Durable Complete Remissions in Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011, 118, 4989-4989.	1.4	1
682	High Response RATE and NO Treatment Related Mortality After Brentuximab Vedotin Salvage Therapy Followed by Reduced Intensity Conditioning Regimen Allogeneic STEM CELL Transplantation (RIC-ALLO) in Patients with CD 30+ Lymphomas. <i>Blood</i> , 2012, 120, 4526-4526.	1.4	1
683	Micafungin Versus Fluconazole Or Itraconazole For Prophylaxis Against Invasive Fungal Infections During Neutropenia In Patients Undergoing Haplo-Identical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 4564-4564.	1.4	1
684	Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party. <i>Blood</i> , 2014, 124, 2573-2573.	1.4	1

#	ARTICLE	IF	CITATIONS
685	Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. Blood, 2015, 126, 1985-1985.	1.4	1
686	Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 3111-3111.	1.4	1
687	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. Blood, 2015, 126, 3214-3214.	1.4	1
688	Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis. Blood, 2016, 128, 3475-3475.	1.4	1
689	Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party. Blood, 2016, 128, 4563-4563.	1.4	1
690	Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 4661-4661.	1.4	1
691	Donor Lymphocyte Infusion after Haploidentical Transplantation with Post-Transplant Cyclophosphamide. Blood, 2016, 128, 5863-5863.	1.4	1
692	Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry.. Blood, 2006, 108, 2991-2991.	1.4	1
693	Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin's Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2006, 108, 3044-3044.	1.4	1
694	The Dose of CD34+ Cells Negatively Impacts the Outcome of Patients Treated with Genoidentical Allo SCT Prepared with a Reduced Intensity Conditioning (RIC).. Blood, 2007, 110, 1086-1086.	1.4	1
695	Comorbidities Index Is Not Predictive of Treatment Related Mortality in Patients (pts) Older Than 60 Years Treated with Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (RIC-ALLO).. Blood, 2009, 114, 1180-1180.	1.4	1
696	Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Lymphocytic Leukemia: a Long Term Analysis From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).. Blood, 2009, 114, 201-201.	1.4	1
697	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. Blood, 2011, 118, 502-502.	1.4	1
698	Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems. Blood, 2012, 120, 734-734.	1.4	1
699	Improved Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Metastatic Renal Cancer Associated with Homozygosity for the HLA-G 14 Base-Pair Deletion Polymorphism: An EBMT STWP Study. Blood, 2012, 120, 4667-4667.	1.4	1
700	Allogeneic Hematopoietic Stem Cell Transplantation for T-Prolymphocytic leukemia: A Retrospective Analysis From the Societe française De Greffe De Moelle Et De Therapie Cellulaire. Blood, 2012, 120, 2008-2008.	1.4	1
701	Treatment of Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome: A Large-Scale Study On Behalf of the Sociéte-Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). Blood, 2012, 120, 593-593.	1.4	1
702	Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis. Blood, 2013, 122, 417-417.	1.4	1

#	ARTICLE	IF	CITATIONS
703	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 1230-1230.	1.4	1
704	Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 2279-2279.	1.4	1
705	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. <i>Blood</i> , 2016, 128, 4655-4655.	1.4	1
706	Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant. <i>Blood</i> , 2017, 130, 851-851.	1.4	1
707	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Mantle Cell Lymphoma Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis. <i>Blood</i> , 2018, 132, 5748-5748.	1.4	1
708	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2018, 132, 4586-4586.	1.4	1
709	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 45-45.	1.4	1
710	Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutics. <i>Blood</i> , 2019, 134, 1993-1993.	1.4	1
711	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. <i>ESMO Open</i> , 2020, 5, e000860.	4.5	1
712	Final Long-Term Results from the Defibrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 1789-1789.	1.4	1
713	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , 2021, 138, 2920-2920.	1.4	1
714	Final Primary Results from the Defibrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 35-36.	1.4	1
715	Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma. , 2022, , 169-171.		1
716	Third autologous stem cell transplants for late relapse of multiple myeloma. <i>Bone Marrow Transplantation</i> , 1996, 17, 885-6.	2.4	1
717	rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response and enhancement of further chemosensitivity. <i>Anticancer Research</i> , 1998, 18, 3699-704.	1.1	1
718	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	2.4	1
719	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 0, . . .	2.4	1
720	Autologous peripheral blood stem cell transplantation (PBSCT) in acute myeloid leukaemia (AML) in first complete remission (CR) a report of the BGMT cooperative group about 32 patients. <i>Hematology and Cell Therapy</i> , 2000, 42, 135-141.	0.7	0

#	ARTICLE	IF	CITATIONS
721	High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party. <i>Bone Marrow Transplantation</i> , 2007, 40, 1045-1048.	2.4	0
722	168: Unrelated Cord Blood Transplantation in Adults with Lymphoid Malignancies. A Eurocord/EBMT-Lymphoma Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 62-63.	2.0	0
723	Prospective Randomized Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (Flu-Bu-ATG) Conditioning for Hematological Malignancies: A Multicenter ITAC Study. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 100-101.	2.0	0
724	5.14 Rituximab in Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia with Fludarabine Plus Total Body Irradiation Conditioning: Results of a Phase 2 Prospective Multicenter Study (ITAC 02-02). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S250-S251.	0.4	0
725	PCN68 Cost-Effectiveness and Quality of Life Analysis of the Multicenter Itac02-01 Study: Prospective Randomized Comparison of Reduced Intensity Versus Non-Myeloablative Conditioning Regimen for Matched Related Allogeneic Stem Cell Transplantation. <i>Value in Health</i> , 2011, 14, A446.	0.3	0
726	An Identical Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic (ALLO) Hematopoietic Stem Cell Transplantation (HSCT) in 222 Patients with Hematologic Malignancies: A Monocenter Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S282.	2.0	0
727	Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S369-S370.	2.0	0
728	Alternative Donor Allogeneic Transplants: Introduction. <i>Seminars in Hematology</i> , 2016, 53, 219-220.	3.4	0
729	T-Replete Haploidentical Allogeneic Transplantation Using Post-Transplantation Cyclophosphamide in Advanced Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S368-S369.	2.0	0
730	ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S36-S37.	2.0	0
731	BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. <i>Hematological Oncology</i> , 2017, 35, 83-84.	1.7	0
732	Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. <i>Cytotherapy</i> , 2017, 19, S16.	0.7	0
733	REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3-4) FLUDARABINE/BUSULFAN-BASED CONDITIONING REGIMENS FOR NON-HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. <i>Hematological Oncology</i> , 2017, 35, 193-194.	1.7	0
734	Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S106-S107.	2.0	0
735	Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S405.	2.0	0
736	Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S406.	2.0	0
737	Checkpoint Inhibition Before Haploidentical Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma (HL) Patients is Associated with Higher PFS without Increased Toxicities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S306-S307.	0.4	0
738	HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP. <i>Hematological Oncology</i> , 2019, 37, 299-300.	1.7	0

#	ARTICLE	IF	CITATIONS
739	IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY). <i>Hematological Oncology</i> , 2019, 37, 300-301.	1.7	0
740	S117 THE ROLE OF ANTI-THYMOCYTE GLOBULIN WITH THIOTEPA-BUSULFAN-FLUDARABINE BASED CONDITIONING IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANT AND POST-TRANSPLANT CYCLOPHOSPHAMIDE. <i>HemaSphere</i> , 2019, 3, 10-11.	2.7	0
741	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e206.	0.4	0
742	Impact of CD34+ Cell Dose on Clinical Outcomes after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from Haploidentical Donors in AML Patients. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S287-S288.	2.0	0
743	Comparison of Matched Sibling, Unrelated and Haploidentical Donor Transplants Using Post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia, a Study of the ALWP EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S57-S58.	2.0	0
744	Calcineurin Inhibitor Alone or in Combination with Mycophenolate Mofetil for Graft-Versus-Host-Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Transplantation from Matched Unrelated Donors: A Study from the ALWP of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S56-S57.	2.0	0
745	Outcomes of Acute Myelogenous Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Total Body Irradiation Versus Chemotherapy-Based Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S110.	2.0	0
746	Haplo Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S285.	2.0	0
747	Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Poor Karnofsky Performance Status Score. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S108.	2.0	0
748	Prognostic impact of early versus late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. <i>European Journal of Haematology</i> , 2021, 106, 708-715.	2.2	0
749	Expect the unexpected. <i>Blood</i> , 2021, 137, 3163-3164.	1.4	0
750	Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy)- the Role of Donor Kinship: From the ALWP of the EBMT. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S236-S237.	1.2	0
751	Alternative donor transplantation for severe aplastic anaemia in 2021: haplo donor, cord blood or both?. <i>British Journal of Haematology</i> , 2021, 193, 863-864.	2.5	0
752	Impact of Plasmacytoid Dendritic Cell (PDC) Recovery on Outcome after Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT).. <i>Blood</i> , 2004, 104, 3794-3794.	1.4	0
753	Stem Cell Transplantation in 281 Patients over 60 Years in Onco Hematologic Malignancies: A Single Center Experience.. <i>Blood</i> , 2004, 104, 5229-5229.	1.4	0
754	A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.. <i>Blood</i> , 2004, 104, 5194-5194.	1.4	0
755	Results of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the FAB M0 Subtype in First Complete Remission: A Survey of the Acute Leukemia Working Party of the European Bone Marrow Transplant Group (EBMT).. <i>Blood</i> , 2004, 104, 5131-5131.	1.4	0
756	Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).. <i>Blood</i> , 2004, 104, 1234-1234.	1.4	0

#	ARTICLE	IF	CITATIONS
757	The Role of Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML): A Donor vs. No Donor Comparison.. Blood, 2004, 104, 2325-2325.	1.4	0
758	Platelets Recovery and Transfusion Needs after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2005, 106, 961-961.	1.4	0
759	Feasibility of High Dose Melphalan and Peripheral Blood Stem Cell Support(IPC-LAM 2000) for Patients over 60 Years with Acute Myeloid Leukemia(AML) in First Remission(CR1):Final Analysis.. Blood, 2005, 106, 2922-2922.	1.4	0
760	Allogeneic Stem Cell Transplantation (allo-SCT) from a HLA Identical Sibling for CR1 AML Patients Aged above 55 Years Old after a Reduced Intensity Conditioning: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).. Blood, 2005, 106, 1140-1140.	1.4	0
761	Impact of Hematopoietic Stem Cell (HSC) Recruitment and Graft Composition on Transplant Outcome after Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Study of the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.. Blood, 2005, 106, 1146-1146.	1.4	0
762	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): A Donor Versus No Donor Comparison.. Blood, 2005, 106, 5413-5413.	1.4	0
763	Fludarabine-Based HLA-Identical Sibling HSCT for Patients with Severe Aplastic Anemia (SAA) Older Than 30 Years: A Study from the French (SFGM-TC) and Italian (GITMO) Registries.. Blood, 2005, 106, 2028-2028.	1.4	0
764	Safety of a Weekly Administration of 7.5 mg/kg of Liposomal Amphotericin B (LAB) for Antifungal Prophylaxis in Patients Receiving High Dose Corticosteroids (CS) for Acute GVHD after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2005, 106, 5348-5348.	1.4	0
765	Impact of Recovery of CD4 and CD8 Lymphocyte Subsets on Acute GVHD after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2005, 106, 1425-1425.	1.4	0
766	Low-Dose Methotrexate as Salvage Therapy for Refractory Graft-Versus-Host Disease (GVHD) after Reduced-Intensity Conditioning (RIC) for Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2005, 106, 1802-1802.	1.4	0
767	Inflammatory Cytokines and Acute Graft-Versus-Host Disease (aGVHD) after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2005, 106, 1810-1810.	1.4	0
768	Lymphoid Chimerism (LC) Kinetic after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2005, 106, 3675-3675.	1.4	0
769	Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Secondary Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS).. Blood, 2005, 106, 5416-5416.	1.4	0
770	Platelets Recovery and Transfusion Needs after Reduced Intensity Conditioning (RIC) Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation (allo-SCT).. Blood, 2006, 108, 2989-2989.	1.4	0
771	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Salvage Treatment for Relapsing Multiple Myeloma (MM): A "Donor" vs. "No Donor" Comparison.. Blood, 2006, 108, 3003-3003.	1.4	0
772	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Refractory or Relapsed Non-Hodgkin's Lymphoma (NHL).. Blood, 2006, 108, 5356-5356.	1.4	0
773	Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1).. Blood, 2006, 108, 3000-3000.	1.4	0
774	Features and Risk Factors of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib.. Blood, 2006, 108, 5098-5098.	1.4	0

#	ARTICLE	IF	CITATIONS
775	AML with 11q23/MLL Abnormalities: A Survey of 146 Cases from French AML Intergroup.. Blood, 2006, 108, 2353-2353.	1.4	0
776	The Use of Recombinant Human Erythropoietin (rHuEpo) after Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation (ASCT) Reduce Red Blood Cell (RBC) Transfusion Requirements.. Blood, 2006, 108, 2988-2988.	1.4	0
777	Plasma Proteomic Profiles May Predict Early Acute Graft-vs.-Host Disease (aGVHD) Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).. Blood, 2006, 108, 2880-2880.	1.4	0
778	Multi-Center Prospective Trial on Conditioning with Treosulfan, Fludarabine and ATG Before Allogeneic HSCT from Unrelated Donors.. Blood, 2007, 110, 4949-4949.	1.4	0
779	Donor Response to G-CSF Is the Best Predictive Factor of Extensive Chronic Graft-Versus-Host Disease after Non Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2007, 110, 2188-2188.	1.4	0
780	Late Events in Patients with Relapsed or Refractory Hodgkin's Lymphoma Treated with an Autologous Stem Cell Transplantation.. Blood, 2007, 110, 834-834.	1.4	0
781	Autologous Stem Cell Transplantation (auto-SCT) in Elderly Patients with Multiple Myeloma (MM): Age per se Does Not Affect Outcome.. Blood, 2007, 110, 947-947.	1.4	0
782	Efficacy of Allogeneic Stem-Cell Transplantation for T/NK-Cell Lymphomas in Adults.. Blood, 2007, 110, 3038-3038.	1.4	0
783	Graft-Versus Host Disease (GVHD) and Infectious Complications Following Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults.. Blood, 2007, 110, 4985-4985.	1.4	0
784	Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a "Donor" Versus "No Donor" Comparison.. Blood, 2007, 110, 1090-1090.	1.4	0
785	Autologous Stem Cell Transplantation (ASCT) for Elderly Patients (≥ 60 Years) with Non-Hodgkin's Lymphoma (NHL): An Analysis Based on EBMT Registry.. Blood, 2007, 110, 1888-1888.	1.4	0
786	Prior High Dose Chemotherapy and a Higher "Intensity" of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).. Blood, 2007, 110, 2001-2001.	1.4	0
787	Rituximab (RTX) as Salvage Therapy for Refractory Chronic Graft-Versus-Host Disease (cGVHD).. Blood, 2007, 110, 2972-2972.	1.4	0
788	Good Safety and Tolerance Profiles of Long Term Treatment of Advanced Multiple Myeloma (MM) with Bortezomib.. Blood, 2007, 110, 4811-4811.	1.4	0
789	Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.. Blood, 2007, 110, 1085-1085.	1.4	0
790	BEAM as a Frontline High Dose Chemotherapy Supported by Autologous PBSCT in Elderly Patients (≥60) Treated with High-Dose (HD) 5-Fluorouracil (5-FU) and Doxorubicin (DOX) /Overlooked.. Blood, 2007, 110, 1910-1910.	1.4	0
791	Early Post-Transplant Administration of Recombinant Erythropoietin Decreases Transfusion Needs and Hastens Haemoglobin Reconstitution in Reduced Intensity Conditioned (RIC) Allogeneic Stem Cell Transplantation (ASCT) for Non-Myeloid Malignancies.. Blood, 2007, 110, 2997-2997.	1.4	0
792	Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT. Blood, 2008, 112, 458-458.	1.4	0

#	ARTICLE	IF	CITATIONS
793	Age and Disease Status Are Important Risk Factors for Outcome after Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults. <i>Blood</i> , 2008, 112, 4412-4412.	1.4	0
794	Prognosis of Patients with AML Carrying 11Q23/MLL Reciprocal Translocations : A Retrospective Study of 191 Cases from the French AML-Intergroup. <i>Blood</i> , 2008, 112, 2547-2547.	1.4	0
795	Feasibility and Efficacy of BEAM as a Frontline High Dose Chemotherapy Supported by Autologous PBSCT in Elderly Patients (≥60 Years) with DLBCL. <i>Blood</i> , 2008, 112, 4449-4449.	1.4	0
796	Prior Treatment with Chemotherapy Associated to Gemtuzumab Ozogamicin (GO) Does Not Increase the Risk of Veno-Occlusive Disease (VOD) after Allogeneic Stem Cell Transplantation (all-SCT).. <i>Blood</i> , 2008, 112, 1121-1121.	1.4	0
797	Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: French Society of Bone Marrow Graft Transplantation and Cellular Therapy Experience. <i>Blood</i> , 2008, 112, 4293-4293.	1.4	0
798	Allogeneic Stem Cell Immunotherapy for Advanced Metastatic Breast Cancer: Lessons from Experience. <i>Blood</i> , 2008, 112, 3903-3903.	1.4	0
799	Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT.. <i>Blood</i> , 2009, 114, 3313-3313.	1.4	0
800	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. <i>Blood</i> , 2009, 114, 1187-1187.	1.4	0
801	Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2009, 114, 3364-3364.	1.4	0
802	Human Development Index Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia.. <i>Blood</i> , 2009, 114, 1193-1193.	1.4	0
803	Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO).. <i>Blood</i> , 2009, 114, 3110-3110.	1.4	0
804	New Strategy for Allogeneic Peripheral Blood Stem Cell Transplantation After Reduced Intensity Conditioning in Multiple Myeloma: Interim Analysis of the IFM2005-03 Study.. <i>Blood</i> , 2009, 114, 4321-4321.	1.4	0
805	Identification of Escape Mechanisms Involved in the Absence of Viral Control Despite Activation of Both Innate (natural killer and gammadelta T cells) and Virus-Specific T Cells in Children with CMV or EBV Disease Following Cord Blood Transplantation.. <i>Blood</i> , 2009, 114, 2659-2659.	1.4	0
806	The Association of Fludarabine, Oral Busulfan and Thymoglobulin Prior to Matched-Related Allo-SCT Allows for High Long Term Outcome for Both Patients with Myeloid or Lymphoid Malignancies and Reveals the Impact of CD34+ Graft Cell Dose On Cgvhd and Outcome: Long Term Analysis of a Homogenous Cohort of 100 Consecutive Patients.. <i>Blood</i> , 2009, 114, 3374-3374.	1.4	0
807	Tandem Auto-Allo in Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR).. <i>Blood</i> , 2009, 114, 3355-3355.	1.4	0
808	Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Societe Francaise de Greffe de Moelle Therapie Cellulaire (SFGM-TC).. <i>Blood</i> , 2009, 114, 1188-1188.	1.4	0
809	Low Relapse without Excessive Transplant-Related Mortality Following Allogeneic Stem Cell Transplantation in Patients with High Risk Secondary Acute Myeloblastic Leukaemia and Myelodysplastic Syndromes, Long-Term Outcomes in a Single Centre Experience.. <i>Blood</i> , 2009, 114, 4308-4308.	1.4	0
810	The Use of Bone Marrow Graft for Hematopoietic Stem Cell Transplantation From Matched Unrelated Donors After Reduced Intensity Conditioning Regimen Improves Survival : Analysis of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. <i>Blood</i> , 2009, 114, 873-873.	1.4	0

#	ARTICLE	IF	CITATIONS
811	Donor Stem Cell Source Does Not Impact Outcome of High Risk (HR) Acute Myeloblastic Leukaemia (AML) Patients After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RIC-ALLO).. Blood, 2009, 114, 4339-4339.	1.4	0
812	Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: The Experience of the French SFGM-TC Group. Blood, 2010, 116, 2392-2392.	1.4	0
813	Pre-Transplant Rituximab Is Associated with Reduced Rate of Acute GvHD After RIC-Allosct In Lymphoma Patients: Results From A Retrospective Monocenter Analysis.. Blood, 2010, 116, 1319-1319.	1.4	0
814	Use of RIC-Allosct In Patients Younger Than 45 Years Old Affected by MDS and Leukemia: A Monocenter Retrospective Analysis.. Blood, 2010, 116, 1316-1316.	1.4	0
815	Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin. Blood, 2010, 116, 1320-1320.	1.4	0
816	Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT. Blood, 2010, 116, 219-219.	1.4	0
817	Rituximab In Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia with Fludarabine + Total Body Irradiation Conditioning: Results of a Phase II Prospective Multicenter Study (ITAC 02-02). Blood, 2010, 116, 3520-3520.	1.4	0
818	Outcome of Relapse After Allogeneic Stem Cell Transplantation (SCT) In Patients with acute Myeloid Leukaemia (AML).. Blood, 2010, 116, 4514-4514.	1.4	0
819	Frontline High Dose Chemotherapy Supported by Autologous PBSCT Might Improve Survival In Elderly Patients (≥60 Years) with High Risk Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 5190-5190.	1.4	0
820	A Phase II Study of Yttrium-90-Ibritumomab Tiuxetan In Combination with a Fludarabine-Based Reduced Intensity Regimen Followed by Allogenic Stem Cell Transplantation In Patients with Relapsed or Chemorefractory CD 20 Positive Non-Hodgkin's Lymphoma.. Blood, 2010, 116, 4565-4565.	1.4	0
821	Disease Status Is the Major Prognosis Factor for Allogenic Transplantation Outcome for Hodgkin Lymphoma: a Retrospective Study From the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Blood, 2010, 116, 2359-2359.	1.4	0
822	Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT.. Blood, 2010, 116, 3447-3447.	1.4	0
823	Reduced Intensity Conditioning Regimens Do Not Offer a Survival Advantage to Myeloma Patients Receiving Allogeneic Stem Cell Hematopoietic Transplantation: A Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC) Registry Study,. Blood, 2011, 118, 4113-4113.	1.4	0
824	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia (AML) with 11q23 (MLL) Rearrangement (MLL-r AML). A Retrospective Analysis From the Acute Leukemia Working Party of EBMT. Blood, 2011, 118, 498-498.	1.4	0
825	Correlation Between Severity of cGvHD and Transplant Outcome: A Retrospective Monocenter Study Based on NIH Classification,. Blood, 2011, 118, 4088-4088.	1.4	0
826	A Combined Evaluation of Severity, Presentation and Duration of Chronic GvHD Predicts Transplant Outcome Among Patients with a Hematological Malignancy Undergoing Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 4549-4549.	1.4	0
827	Impact of Chronic Graft-Versus-Host disease (GVHD) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) As Treatment for Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of the EBMT. Blood, 2011, 118, 321-321.	1.4	0
828	Diffuse Large B-Cell Lymphoma in the Elderly: Outcome of Patients From a Single Center. Blood, 2011, 118, 2693-2693.	1.4	0

#	ARTICLE	IF	CITATIONS
829	Yttrium-90-Ibritumomab Tiuxetan (Zevalin) in Combination with a Fludarabine-Based Reduced Conditioning Regimen (RIC) Followed by Allogeneic Stem Cell Transplantation for Advanced/Aggressive Non-Hodgkin's Lymphoma (NHL): A Prospective, Multicentre, Open Phase II Study. <i>Blood</i> , 2011, 118, 3027-3027.	1.4	0
830	Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 335-335.	1.4	0
831	Combination of Cytarabine and Topotecan Improves Response Rate for Patients Treated for Acute Myeloid Leukemia with Persistent Disease After Frontline Induction. <i>Blood</i> , 2011, 118, 2605-2605.	1.4	0
832	Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT). <i>Blood</i> , 2011, 118, 3057-3057.	1.4	0
833	Lenalidomide Followed with Donor Lymphocytes Infusion (DLI) After Allogeneic Stem-Cell Transplantation (Allo-SCT) with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma. <i>Blood</i> , 2011, 118, 4310-4310.	1.4	0
834	Acute Gvhd Is a Strong Predictor of Full Donor cd3+ t Cells Chimerism (TCC) After Reduced Intensity Conditioning (RIC) for Allogeneic Stem Cell Transplantation (Allo-SCT). <i>Blood</i> , 2011, 118, 4545-4545.	1.4	0
835	Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma. <i>Blood</i> , 2011, 118, 4456-4456.	1.4	0
836	Autologous Transplantation Followed by Reduced-Intensity Allogeneic Transplantation Is Feasible in Patients with High-Risk Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 3105-3105.	1.4	0
837	LOW Transplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.. <i>Blood</i> , 2012, 120, 3031-3031.	1.4	0
838	The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning.. <i>Blood</i> , 2012, 120, 3029-3029.	1.4	0
839	Post-Transplant Outcome in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome Who Received Conditioning Regimen Based On Fludarabine, Busulfan and Anti-Thymoglobulin Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 2013-2013.	1.4	0
840	Risk Factors to Develop Sclerotic Chronic GvHD After Allogeneic HSCT: Preliminary Results of a Multicentre Retrospective study From the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC). <i>Blood</i> , 2012, 120, 1947-1947.	1.4	0
841	NK Cells Display Poor Anti Lymphoma and AML Function At Early Times Following Allogeneic HLA-Identical SCT for Leukemia and Lymphomas.. <i>Blood</i> , 2012, 120, 3045-3045.	1.4	0
842	Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2012, 120, 1929-1929.	1.4	0
843	High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT).. <i>Blood</i> , 2012, 120, 3148-3148.	1.4	0
844	Pilot Study of Lenalidomide-Rituximab Combination in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 3695-3695.	1.4	0
845	Risk Factors of GANCICLOVIR-RELATED Neutropenia After Allogeneic STEM CELL Transplantation: A Retrospective Monocenter Study On 547 Patients. <i>Blood</i> , 2012, 120, 4186-4186.	1.4	0
846	Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.. <i>Blood</i> , 2012, 120, 3116-3116.	1.4	0

#	ARTICLE	IF	CITATIONS
847	Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2012, 120, 4153-4153.	1.4	0
848	Reduced toxicity conditioning. <i>Hematologie</i> , 2013, 19, 183-188.	0.0	0
849	Role Of Allogeneic Transplant In Poor Risk CLL Patients: A Long-Term Monocentric Experience In 39 Patients. <i>Blood</i> , 2013, 122, 5531-5531.	1.4	0
850	Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT). <i>Blood</i> , 2013, 122, 3334-3334.	1.4	0
851	Bone Marrow (BM) Versus Peripheral Blood Stem Cell (PBSC) For Haploidentical Transplantation With Nonmyeloblastic (NMA) Conditioning Regimen and Post Infusion Cyclophosphamide. <i>Blood</i> , 2013, 122, 2119-2119.	1.4	0
852	Allogeneic Hematopoietic Stem Cell Transplantation From Haploidentical Donor After Reduced Intensity Conditioning Regimen Allows Promising Disease Control In Patients With Hematological Diseases. <i>Blood</i> , 2013, 122, 2139-2139.	1.4	0
853	Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe FranÃ§aise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). <i>Blood</i> , 2013, 122, 3373-3373.	1.4	0
854	Use Of Unrelated Donors In Elderly Patients (age >60 years) Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 5544-5544.	1.4	0
855	Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up. <i>Blood</i> , 2013, 122, 3364-3364.	1.4	0
856	Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmw of the EBMT. <i>Blood</i> , 2014, 124, 2530-2530.	1.4	0
857	Bortezomib As Salvage Treatment for Multiple Myeloma Relapsing after Allogeneic Haematopoietic Stem Cell Transplantation: Efficacy, Tolerance and Modulation of Graft Versus Host Disease: A Study of the French Society for Stem Cell Transplantation and Cell Therapies (SFGM-TC). <i>Blood</i> , 2014, 124, 3959-3959.	1.4	0
858	Effect of Immune Modulation for Peripheral T-Cell Lymphoma in Response to Relapse after Allogeneic Hematopoietic Stem Cell Transplant: A Study of 63 Patients By the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).. <i>Blood</i> , 2014, 124, 3963-3963.	1.4	0
859	Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties. <i>Blood</i> , 2014, 124, 185-185.	1.4	0
860	Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 3863-3863.	1.4	0
861	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014, 124, 681-681.	1.4	0
862	Contribution of IPSS-R Cytogenetics to Predict Outcome after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study from the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). <i>Blood</i> , 2014, 124, 5609-5609.	1.4	0
863	Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT. <i>Blood</i> , 2014, 124, 2581-2581.	1.4	0
864	Impact of CD3+ and CD34+ Doses in the Mobilized Peripheral Blood Stem Cell Grafts on the Outcome of Reduced-Intensity Conditioning Allogenic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia " an Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2014, 124, 190-190.	1.4	0

#	ARTICLE	IF	CITATIONS
865	Tacrolimus (FK) Compared to Cyclosporine a (CyA) after Haploidentical T Cell Replete Stem Cell Transplantation (Haplo-SCT) with Post-Infusion Cyclophosphamide: A Retrospective Analysis. <i>Blood</i> , 2014, 124, 3902-3902.	1.4	0
866	Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2014, 124, 3945-3945.	1.4	0
867	Impact of Partial Response Versus Complete Response before RIC/RTC Allogeneic Stem Cell Transplantation on Survival in a Cohort of 115 Chemosensitive Advanced NHL. <i>Blood</i> , 2014, 124, 1246-1246.	1.4	0
868	Effect of Graft Source on Alternative Unrelated Donor Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukaemia after: A Study from the SFGM-TC. <i>Blood</i> , 2014, 124, 2541-2541.	1.4	0
869	The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio. <i>Blood</i> , 2014, 124, 323-323.	1.4	0
870	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 1216-1216.	1.4	0
871	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014, 124, 1227-1227.	1.4	0
872	Tribute to Josy Reiffers. <i>Hematologie</i> , 2015, 21, 325-325.	0.0	0
873	Allogeneic HSCT for Patients Aged More Than 55 Years with Myeloid Malignancies: Results of 171 Patients. <i>Blood</i> , 2015, 126, 5525-5525.	1.4	0
874	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 4364-4364.	1.4	0
875	Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 3216-3216.	1.4	0
876	Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2015, 126, 1958-1958.	1.4	0
877	Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 926-926.	1.4	0
878	Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2015, 126, 155-155.	1.4	0
879	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 2021-2021.	1.4	0
880	Single Center Experience of Allogenic Hematopoietic Stem Cell Transplantation in 100 Patients with Myelodysplasia: The Impact of Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 5537-5537.	1.4	0
881	Brentuximab Vedotin Followed By Allogeneic Stem-Cell Transplantation for Patients with CD30 Anaplastic or T Cell Non Hodgkin Lymphomas: A Study on Behalf of the SFGM-TC.. <i>Blood</i> , 2015, 126, 4377-4377.	1.4	0
882	Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). <i>Blood</i> , 2015, 126, 4367-4367.	1.4	0

#	ARTICLE	IF	CITATIONS
883	CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC. Blood, 2015, 126, 1908-1908.	1.4	0
884	The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2015, 126, 3110-3110.	1.4	0
885	Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen. Blood, 2015, 126, 4373-4373.	1.4	0
886	Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. Blood, 2016, 128, 3484-3484.	1.4	0
887	Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of Tj ETQq1 1 0.784314 rgBT /Over	1.4	0
888	Impact of Cytopenia Following Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2016, 128, 2281-2281.	1.4	0
889	Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP). Blood, 2016, 128, 4701-4701.	1.4	0
890	Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Transplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT. Blood, 2016, 128, 4643-4643.	1.4	0
891	Reduced-Intensity (FB2) Vs Reduced-Toxicity Myeloablative (FB3/FB4) Fludarabine/Busulfan Based Conditioning Regimens for Non-Hodgkin Lymphoma (NHL) Allografted Adult Patients: A Retrospective Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Blood, 2016, 128, 980-980.	1.4	0
892	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. Blood, 2016, 128, 3467-3467.	1.4	0
893	Revisiting Graft-Versus-Leukemia Effects after Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia : A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2016, 128, 2244-2244.	1.4	0
894	Chimerism Analysis after Haploidentical Stem Cell Transplantation: Is It Necessary for All Patients?. Blood, 2016, 128, 3417-3417.	1.4	0
895	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) with Complex Karyotypes (CK): A Retrospective Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) and MD Anderson Cancer Center (MDACC). Blood, 2016, 128, 3479-3479.	1.4	0
896	Triage Scoring System Based on Early Post-Transplant Complications for Patients with Myelodysplastic Syndrome Requiring ICU after Allo-HCT: An SFGM-TC Study. Blood, 2016, 128, 3470-3470.	1.4	0
897	Early Post Transplant Organ Toxicity after Allogeneic One-Haplotype Mismatch (Haplo) Hematopoietic Stem Cell Transplant (HSCT). Blood, 2016, 128, 5754-5754.	1.4	0
898	Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy). Blood, 2016, 128, 4594-4594.	1.4	0
899	Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry. Blood, 2016, 128, 3476-3476.	1.4	0
900	Pretransplantation Myeloablative Conditioning Regimen with Intravenous Busulfan Dose Adjustment for Older Patients with Hematologic Malignancies. Blood, 2016, 128, 5751-5751.	1.4	0

#	ARTICLE	IF	CITATIONS
901	Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 4618-4618.	1.4	0
902	The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 666-666.	1.4	0
903	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3504-3504.	1.4	0
904	Evaluation of Infectious Complications after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Following Reduced-Intensity and Myeloablative Conditioning: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) Study. <i>Blood</i> , 2016, 128, 5758-5758.	1.4	0
905	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. <i>Blood</i> , 2017, 130, 907-907.	1.4	0
906	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2017, 130, 850-850.	1.4	0
907	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2017, 130, 852-852.	1.4	0
908	Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT. <i>Blood</i> , 2018, 132, 2174-2174.	1.4	0
909	Better Outcome in Children Compared to AYAs and Young Adults after Allogeneic HSCT for AML: A Multicenter Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM -TC). <i>Blood</i> , 2018, 132, 3449-3449.	1.4	0
910	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation – a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 3464-3464.	1.4	0
911	Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of the Francophone Society for Stem Cell Transplantation and Cell Therapy. <i>Blood</i> , 2018, 132, 3447-3447.	1.4	0
912	Prognostic Value of Cpss Cytogenetic Risk Classification in Patients with CMML after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2182-2182.	1.4	0
913	Outcomes after Unrelated Cord Blood Transplantation (UCBT) in Patients with Chronic Myeloid Leukemia (CML): A Retrospective Study from the Cmw-EBMT. <i>Blood</i> , 2018, 132, 3475-3475.	1.4	0
914	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 1016-1016.	1.4	0
915	Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome:the SFGM-TC Experience. <i>Blood</i> , 2018, 132, 3457-3457.	1.4	0
916	Clinical Outcome Associated with Cytomegalovirus (CMV) Infection/Disease in CMV-Seropositive Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 3382-3382.	1.4	0
917	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 609-609.	1.4	0
918	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC. <i>Blood</i> , 2018, 132, 4663-4663.	1.4	0

#	ARTICLE	IF	CITATIONS
919	PS1246 GRAFT SOURCE AND PRE-TRANSPLANT DISEASE STATUS ARE THE MAIN VARIABLES AFFECTING THE OUTCOME OF T CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR HODGKIN LYMPHOMA. <i>HemaSphere</i> , 2019, 3, 568.	2.7	0
920	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2019, 134, 148-148.	1.4	0
921	Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT. <i>Blood</i> , 2019, 134, 4548-4548.	1.4	0
922	Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT. <i>Blood</i> , 2019, 134, 3274-3274.	1.4	0
923	Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients. <i>Blood</i> , 2019, 134, 4625-4625.	1.4	0
924	CD34+ Cell Dose Effects on Clinical Outcomes of Patients with Acute Myeloid Leukemia after T-Replete Haploidentical Allogeneic Hematopoietic Stemcell Transplantation Using Peripheral Blood Stem Cells. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2019, 134, 4586-4586.	1.4	0
925	Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Unrelated Cord Blood in Patients with T-Cell Non-Hodgkin Lymphoma : A Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGMC-TC). <i>Blood</i> , 2019, 134, 4596-4596.	1.4	0
926	Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2019, 134, 2053-2053.	1.4	0
927	Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT. <i>Blood</i> , 2019, 134, 589-589.	1.4	0
928	A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Venous Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2019, 134, 1972-1972.	1.4	0
929	CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy. <i>Blood</i> , 2019, 134, 4484-4484.	1.4	0
930	Pre-Transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed By Haploidentical HSCT for Relapsed/Refractory Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Study. <i>Blood</i> , 2019, 134, 3213-3213.	1.4	0
931	Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 3338-3338.	1.4	0
932	Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies. <i>Blood</i> , 2019, 134, 4503-4503.	1.4	0
933	Long-Term Outcome of Peripheral Blood Autologous Stem Cell Transplantation (AutoSCT) for De Novo Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Vs Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 1840-1840.	1.4	0
934	Higher Grade Cytokine Release Syndrome Is a Predictive Factor for Gvhd in Haploidentical Stem Cell Transplantation with Peripheral Blood Cell. <i>Blood</i> , 2021, 138, 2881-2881.	1.4	0
935	Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1). <i>Blood</i> , 2021, 138, 3910-3910.	1.4	0
936	Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party. <i>Blood</i> , 2021, 138, 1809-1809.	1.4	0

#	ARTICLE	IF	CITATIONS
937	Allogeneic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post Transplant Cyclophosphamide (PTCy). a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2021, 138, 3916-3916.	1.4	0
938	Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3954-3954.	1.4	0
939	Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3953-3953.	1.4	0
940	Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 3964-3964.	1.4	0
941	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 9-9.	1.4	0
942	10. Thérapie allogène et cellules Natural Killer. , 2020, , 177-188.		0
943	NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
944	Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
945	Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
946	Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
947	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
948	10. Thérapie allogène et cellules Natural Killer. , 2020, , 177-188.		0
949	Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
950	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Transplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
951	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
952	Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020, 136, 24-25.	1.4	0
953	Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
954	Histological evolution of peripheral T-cell lymphomas. Study of six cases. <i>Pathologie Et Biologie</i> , 1991, 39, 692-6.	2.2	0

#	ARTICLE	IF	CITATIONS
955	Haploidentical Versus Matched Unrelated Donor Transplants for Lymphomas Using Post-Transplant Cyclophosphamide: A Joint CIBMTR/EBMT Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S76-S77.	1.2	0
956	Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis. <i>Acta Haematologica</i> , 2022, 145, 419-429.	1.4	0
957	Defibrotide (DF) Treatment in Pediatric (ped) and Adult Patients (pts) with Severe or Very Severe Venous Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Final Results from the Defifrance Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S18-S19.	1.2	0
958	Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide (DF) for the Treatment of Severe/Very Severe Venous Occlusive Disease/ Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT). <i>Transplantation and Cellular Therapy</i> , 2022, 28, S150-S151.	1.2	0